Rossari Biotech LimitedQ1 FY27 Results & Financial Update
Rossari Biotech Limited: Q1 FY27 consolidated results and company financials – revenue ₹697.20 Cr, PAT ₹35.10 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Rossari Biotech price & chart
Market price₹429.10
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Rossari Biotech Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Rossari Biotech delivered a strong financial performance for the first quarter of fiscal year 2027, posting its highest-ever quarterly revenue from operations at Rs. 697.2 crore, representing a robust 28% year-on-year expansion.
Growth during the quarter was broad-based and supported by healthy domestic business momentum and continued expansion across international markets.
On a segmental basis, the HPPC, TSC, and AHN businesses recorded solid year-on-year growth rates of 28%, 28%, and 27% respectively, reflecting healthy demand right across the portfolio.
Consolidated EBITDA for the quarter stood at Rs. 80.6 crore, marking a 19% improvement compared to the same period in the previous year, with an EBITDA margin of 11.6%.
Consolidated Profit After Tax (PAT) reached Rs. 35.1 crore, higher by 4% compared to Rs. 33.6 crore reported in Q1 FY26, resulting in a diluted EPS of Rs. 6.3 for the quarter.
During the quarter, the company further strengthened its international and regional presence by establishing a greenfield blending facility in Thailand through its subsidiary, Unistar Thai.
The company also advanced its non-core asset monetization strategy by successfully completing the sale of its Andheri office during the quarter, following the previous quarter's sale of its Kanjurmarg office.
01 · Business model
What does Rossari Biotech do?
Rossari Biotech Limited is a prominent specialty-chemicals manufacturer headquartered in Mumbai, India, providing intelligent and sustainable solutions for diverse end-user industries.
The company operates strategically located manufacturing facilities in Silvassa and Dahej, catering to tailor-made chemical requirements across home care, personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition (AHN).
Rossari's operations are divided into three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN).
The company reaches customers through an extensive, dedicated network of distributors spread all over India, alongside an expanding international footprint supported by global partnerships.
02 · Historical context
What shaped the business before this quarter
The company previously completed the sale of its Kanjurmarg office prior to the current quarter, which was followed by the sale of its Andheri office during Q1 FY27.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹697.20 Cr | ₹543.72 Cr | — |
| Total income | ₹697.20 Cr | ₹543.72 Cr | ₹2,396.37 Cr |
| Profit before tax | ₹47.67 Cr | ₹46.10 Cr | ₹202.52 Cr |
| Profit after tax | ₹35.10 Cr | ₹33.60 Cr | ₹149.21 Cr |
| EPS | ₹6.34 | ₹6.07 | ₹26.95 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 5.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 6.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue growth of 28% YoY to Rs. 697.2 crore was driven by healthy momentum in the domestic business and continued expansion of the company's international presence.
All three business segments contributed positively, with HPPC, TSC, and AHN posting year-on-year revenue growth of 28%, 28%, and 27% respectively.
Performance was supported by deeper market penetration, expansion into new applications, and a higher contribution from differentiated, value-added specialty solutions.
What drove margins
Consolidated EBITDA for Q1 FY27 reached Rs. 80.6 crore, representing an EBITDA margin of 11.6% compared with 12.5% in the corresponding quarter of the previous year.
05 · Demand, customers & order book
Where demand is coming from
International business progress was supported by higher wallet shares with global partners and growing acceptance of specialty solutions in overseas markets.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The Home, Personal Care and Performance Chemicals (HPPC) business registered a robust 28% year-on-year growth during the quarter.
The Textile Specialty Chemicals (TSC) business delivered a 28% year-on-year increase in revenues.
The Animal Health and Nutrition (AHN) business recorded a 27% year-on-year growth rate for the quarter.
Geography and market mix
The company established a greenfield blending facility in Thailand via subsidiary Unistar Thai, featuring an installed capacity of 5,000 MTPA to serve Southeast Asia.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Management noted that capacity utilization across past investments has been improving steadily, with priority now placed on driving optimal utilization and operational efficiencies.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The Thailand facility was specifically designed to offer customized formulations aligned with local market requirements and to improve supply-chain efficiency.
09 · Reported developments
What changed operationally
Achieved highest-ever quarterly revenue of Rs. 697.2 crore and highest-ever quarterly EBITDA of Rs. 80.6 crore in Q1 FY27.
10 · Previous-quarter changes
What changed since the previous quarter
Completed the sale of the Kanjurmarg office in the preceding quarter, preceding the Andheri office sale completed in Q1 FY27.
11 · Key Q&A
The quarter, answered directly
What does Rossari Biotech do?
Rossari Biotech Limited is a prominent specialty-chemicals manufacturer headquartered in Mumbai, India, providing intelligent and sustainable solutions for diverse end-user industries.
What is the clearest takeaway from Q1 FY27?
Rossari Biotech delivered a strong financial performance for the first quarter of fiscal year 2027, posting its highest-ever quarterly revenue from operations at Rs. 697.2 crore, representing a robust 28% year-on-year expansion.
What drove revenue or demand?
Revenue growth of 28% YoY to Rs. 697.2 crore was driven by healthy momentum in the domestic business and continued expansion of the company's international presence.
What mattered most for margins or profitability?
Consolidated EBITDA for Q1 FY27 reached Rs. 80.6 crore, representing an EBITDA margin of 11.6% compared with 12.5% in the corresponding quarter of the previous year.
What changed operationally beyond the headline numbers?
Management noted that capacity utilization across past investments has been improving steadily, with priority now placed on driving optimal utilization and operational efficiencies.
What should the next disclosure help confirm?
Monitor the operational progress and capacity utilization ramp-up of the newly established Thailand blending facility.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Capacity Utilization Ramp-up: Monitor the operational progress and capacity utilization ramp-up of the newly established Thailand blending facility.
- 02
Segment Performance Continuity: Track ongoing growth momentum across the HPPC, TSC, and AHN business segments in upcoming quarters.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.